# MATINS (NCT03733990)

> A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03733990
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Faron Pharmaceuticals Ltd
- Conditions: Cancer
- Interventions: FP-1305 (bexmarilimab)
- Enrollment: 216
- Primary outcome: Dose Limiting Toxicities (DLT) in the Trial Subjects.
- Primary outcome: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
- Primary outcome: The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
- Primary outcome: The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.

## Indexed commentary on MATINS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=matins-nct03733990